Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.

Loos J, Pfeuffer S, Pape K, Ruck T, Luessi F, Spreer A, Zipp F, Meuth SG, Bittner S.

J Neurol. 2020 Feb 13. doi: 10.1007/s00415-020-09755-x. [Epub ahead of print]

PMID:
32055995
2.

Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H.

Nat Rev Neurol. 2020 Feb;16(2):125. doi: 10.1038/s41582-020-0310-1.

PMID:
31937911
3.

Web-ARM: A Web-Based Interface for the Automatic Construction of QM/MM Models of Rhodopsins.

Pedraza-González L, Marín MDC, Jorge AN, Ruck TD, Yang X, Valentini A, Olivucci M, De Vico L.

J Chem Inf Model. 2020 Feb 10. doi: 10.1021/acs.jcim.9b00615. [Epub ahead of print]

PMID:
31909998
4.

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses.

Pfeuffer S, Rolfes L, Bormann E, Sauerland C, Ruck T, Schilling M, Melzer N, Brand M, Pul R, Kleinschnitz C, Wiendl H, Meuth SG.

J Clin Med. 2019 Dec 22;9(1). pii: E35. doi: 10.3390/jcm9010035.

5.

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.

Möhn N, Pfeuffer S, Ruck T, Gross CC, Skripuletz T, Klotz L, Wiendl H, Stangel M, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Dec 11;7(2). pii: e654. doi: 10.1212/NXI.0000000000000654. Print 2020 Mar.

6.

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination.

Rolfes L, Pawlitzki M, Pfeuffer S, Thomas C, Schmidt-Chanasit J, Gross CC, Schulte-Mecklenbeck A, Wiendl H, Meuth SG, M Grauer O, Ruck T.

Int J Mol Sci. 2019 Nov 28;20(23). pii: E5985. doi: 10.3390/ijms20235985.

7.

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.

Rolfes L, Pfeuffer S, Ruck T, Windhagen S, Oschlies I, Pavenstädt HJ, Angenendt L, Wiendl H, Krämer J, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1). pii: e638. doi: 10.1212/NXI.0000000000000638. Print 2020 Jan. No abstract available. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2019 Dec 5;7(1):.

8.

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.

Keller CW, Ruck T, McHugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, Klotz L, Meuth SG, Münz C, Nimmerjahn F, Wiendl H, Lünemann JD.

Ann Clin Transl Neurol. 2019 Dec;6(12):2586-2594. doi: 10.1002/acn3.50935. Epub 2019 Nov 4.

9.

Skeletal muscle as potential central link between sarcopenia and immune senescence.

Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T.

EBioMedicine. 2019 Nov;49:381-388. doi: 10.1016/j.ebiom.2019.10.034. Epub 2019 Oct 26. Review.

10.

β1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells.

Birkner K, Wasser B, Ruck T, Thalman C, Luchtman D, Pape K, Schmaul S, Bitar L, Krämer-Albers EM, Stroh A, Meuth SG, Zipp F, Bittner S.

J Clin Invest. 2020 Feb 3;130(2):715-732. doi: 10.1172/JCI126381.

11.

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H.

Nat Rev Neurol. 2020 Jan;16(1):56-62. doi: 10.1038/s41582-019-0268-z. Epub 2019 Oct 24. Review. Erratum in: Nat Rev Neurol. 2020 Feb;16(2):125.

PMID:
31649335
12.

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review.

Rolfes L, Pfeuffer S, Ruck T, Melzer N, Pawlitzki M, Heming M, Brand M, Wiendl H, Meuth SG.

J Clin Med. 2019 Oct 4;8(10). pii: E1623. doi: 10.3390/jcm8101623. Review.

13.

Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies.

Fischer N, Preuße C, Radke J, Pehl D, Allenbach Y, Schneider U, Feist E, von Casteleyn V, Hahn K, Ruck T, Meuth SG, Goebel HH, Graf R, Mammen A, Benveniste O, Stenzel W.

Brain Pathol. 2019 Aug 3. doi: 10.1111/bpa.12772. [Epub ahead of print]

PMID:
31376301
14.

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Ruck T, Schulte-Mecklenbeck A, Pfeuffer S, Heming M, Klotz L, Windhagen S, Kleinschnitz C, Gross CC, Wiendl H, Meuth SG.

EBioMedicine. 2019 Aug;46:381-386. doi: 10.1016/j.ebiom.2019.07.062. Epub 2019 Jul 29.

15.

Dysphagia as Isolated Manifestation of Jo-1 Associated Myositis?

Labeit B, Muhle P, Suntrup-Krueger S, Ahring S, Ruck T, Dziewas R, Warnecke T.

Front Neurol. 2019 Jul 9;10:739. doi: 10.3389/fneur.2019.00739. eCollection 2019.

16.

The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.

Hundehege P, Cerina M, Eichler S, Thomas C, Herrmann AM, Göbel K, Müntefering T, Fernandez-Orth J, Bock S, Narayanan V, Budde T, Speckmann EJ, Wiendl H, Schubart A, Ruck T, Meuth SG.

Neural Regen Res. 2019 Nov;14(11):1950-1960. doi: 10.4103/1673-5374.259622.

17.

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.

Haas J, Würthwein C, Korporal-Kuhnke M, Viehoever A, Jarius S, Ruck T, Pfeuffer S, Meuth SG, Wildemann B.

Front Immunol. 2019 Jun 4;10:1204. doi: 10.3389/fimmu.2019.01204. eCollection 2019.

18.

Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease.

Schröder JB, Marian T, Claus I, Muhle P, Pawlowski M, Wiendl H, Suntrup-Krueger S, Meuth SG, Dziewas R, Ruck T, Warnecke T.

Front Neurol. 2019 Apr 16;10:386. doi: 10.3389/fneur.2019.00386. eCollection 2019.

19.

Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration.

Birkner K, Loos J, Gollan R, Steffen F, Wasser B, Ruck T, Meuth SG, Zipp F, Bittner S.

Front Neurol. 2019 Mar 12;10:205. doi: 10.3389/fneur.2019.00205. eCollection 2019.

20.

Isolation of Primary Murine Skeletal Muscle Microvascular Endothelial Cells.

Müntefering T, Michels APE, Pfeuffer S, Meuth SG, Ruck T.

J Vis Exp. 2019 Mar 6;(145). doi: 10.3791/58901.

PMID:
30907887
21.

Understanding the burden of refractory myasthenia gravis.

Schneider-Gold C, Hagenacker T, Melzer N, Ruck T.

Ther Adv Neurol Disord. 2019 Mar 1;12:1756286419832242. doi: 10.1177/1756286419832242. eCollection 2019. Review.

22.

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease.

Schröder JB, Pawlowski M, Meyer Zu Hörste G, Gross CC, Wiendl H, Meuth SG, Ruck T, Warnecke T.

Front Neurol. 2018 Dec 18;9:1081. doi: 10.3389/fneur.2018.01081. eCollection 2018.

23.

Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Göbel K, Asaridou CM, Merker M, Eichler S, Herrmann AM, Geuß E, Ruck T, Schüngel L, Groeneweg L, Narayanan V, Schneider-Hohendorf T, Gross CC, Wiendl H, Kehrel BE, Kleinschnitz C, Meuth SG.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116. Epub 2018 Dec 17.

24.

Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis.

Hundehege P, Fernandez-Orth J, Römer P, Ruck T, Müntefering T, Eichler S, Cerina M, Epping L, Albrecht S, Menke AF, Birkner K, Göbel K, Budde T, Zipp F, Wiendl H, Gorji A, Bittner S, Meuth SG.

Neurosignals. 2018;26(1):77-93. doi: 10.1159/000495425. Epub 2018 Nov 27. Review.

25.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.

PMID:
30446966
26.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.

Neurology. 2018 Dec 11;91(24):e2233-e2237. doi: 10.1212/WNL.0000000000006648. Epub 2018 Nov 7.

27.

Intubation, tracheostomy, and decannulation in patients with Guillain-Barré-syndrome-does dysphagia matter?

Schröder JB, Marian T, Muhle P, Claus I, Thomas C, Ruck T, Wiendl H, Warnecke T, Suntrup-Krueger S, Meuth S, Dziewas R.

Muscle Nerve. 2019 Feb;59(2):194-200. doi: 10.1002/mus.26377. Epub 2018 Dec 18.

PMID:
30390307
28.

Human T cells in silico: Modelling dynamic intracellular calcium and its influence on cellular electrophysiology.

Eichinger P, Herrmann AM, Ruck T, Herty M, Gola L, Kovac S, Budde T, Meuth SG, Hundehege P.

J Immunol Methods. 2018 Oct;461:78-84. doi: 10.1016/j.jim.2018.06.020. Epub 2018 Jul 3.

PMID:
30158076
29.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
30.

Skeletal muscle cells actively shape (auto)immune responses.

Afzali AM, Müntefering T, Wiendl H, Meuth SG, Ruck T.

Autoimmun Rev. 2018 May;17(5):518-529. doi: 10.1016/j.autrev.2017.12.005. Epub 2018 Mar 9. Review.

PMID:
29526638
31.

[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].

Meuth SG, Ruck T, Aktas O, Hartung HP.

Nervenarzt. 2018 Aug;89(8):895-907. doi: 10.1007/s00115-018-0498-0. Review. German.

PMID:
29523912
32.

Cytokine signaling in multiple sclerosis: Lost in translation.

Göbel K, Ruck T, Meuth SG.

Mult Scler. 2018 Apr;24(4):432-439. doi: 10.1177/1352458518763094. Epub 2018 Mar 7. Review.

PMID:
29512406
33.

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.

Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG, Johnen A.

Front Neurol. 2018 Jan 16;8:730. doi: 10.3389/fneur.2017.00730. eCollection 2017.

34.

Increase of Substance P Concentration in Saliva after Pharyngeal Electrical Stimulation in Severely Dysphagic Stroke Patients - an Indicator of Decannulation Success?

Muhle P, Suntrup-Krueger S, Bittner S, Ruck T, Claus I, Marian T, Schröder JB, Minnerup J, Warnecke T, Meuth SG, Dziewas R.

Neurosignals. 2017;25(1):74-87. doi: 10.1159/000482002. Epub 2017 Oct 17.

35.

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function.

Kleffner I, Eichler S, Ruck T, Schüngel L, Pfeuffer S, Polzer P, Dittrich R, Dziewas R, Gross CC, Göbel K, Wiendl H, Kehrel BE, Meuth SG.

Front Neurol. 2017 Sep 28;8:517. doi: 10.3389/fneur.2017.00517. eCollection 2017.

36.

TRPC6 channels modulate the response of pancreatic stellate cells to hypoxia.

Nielsen N, Kondratska K, Ruck T, Hild B, Kovalenko I, Schimmelpfennig S, Welzig J, Sargin S, Lindemann O, Christian S, Meuth SG, Prevarskaya N, Schwab A.

Pflugers Arch. 2017 Dec;469(12):1567-1577. doi: 10.1007/s00424-017-2057-0. Epub 2017 Aug 28.

PMID:
28849300
37.

Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.

Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 2. Review.

38.

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.

PLoS One. 2017 Apr 13;12(4):e0174858. doi: 10.1371/journal.pone.0174858. eCollection 2017.

39.

Nanomechanics of the endothelial glycocalyx contribute to Na+-induced vascular inflammation.

Schierke F, Wyrwoll MJ, Wisdorf M, Niedzielski L, Maase M, Ruck T, Meuth SG, Kusche-Vihrog K.

Sci Rep. 2017 Apr 13;7:46476. doi: 10.1038/srep46476.

40.

Recombinant tandem of pore-domains in a Weakly Inward rectifying K+ channel 2 (TWIK2) forms active lysosomal channels.

Bobak N, Feliciangeli S, Chen CC, Ben Soussia I, Bittner S, Pagnotta S, Ruck T, Biel M, Wahl-Schott C, Grimm C, Meuth SG, Lesage F.

Sci Rep. 2017 Apr 5;7(1):649. doi: 10.1038/s41598-017-00640-8.

41.

Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?

Afzali AM, Ruck T, Wiendl H, Meuth SG.

Autoimmun Rev. 2017 May;16(5):478-494. doi: 10.1016/j.autrev.2017.03.001. Epub 2017 Mar 7. Review.

42.

Isolated dysphagia as initial sign of anti-IgLON5 syndrome.

Schröder JB, Melzer N, Ruck T, Heidbreder A, Kleffner I, Dittrich R, Muhle P, Warnecke T, Dziewas R.

Neurol Neuroimmunol Neuroinflamm. 2016 Nov 22;4(1):e302. eCollection 2017 Jan.

43.

Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.

Pfeuffer S, Beuker C, Ruck T, Lenze F, Wiendl H, Melzer N, Meuth SG.

Neurology. 2016 Nov 29;87(22):2380-2381. Epub 2016 Oct 28. No abstract available.

PMID:
27794114
44.

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

Gross CC, Ahmetspahic D, Ruck T, Schulte-Mecklenbeck A, Schwarte K, Jörgens S, Scheu S, Windhagen S, Graefe B, Melzer N, Klotz L, Arolt V, Wiendl H, Meuth SG, Alferink J.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289. eCollection 2016 Dec.

45.

14-3-3 Proteins regulate K2P 5.1 surface expression on T lymphocytes.

Fernández-Orth J, Ehling P, Ruck T, Pankratz S, Hofmann MS, Landgraf P, Dieterich DC, Smalla KH, Kähne T, Seebohm G, Budde T, Wiendl H, Bittner S, Meuth SG.

Traffic. 2017 Jan;18(1):29-43. doi: 10.1111/tra.12455. Epub 2016 Nov 27.

46.

The quality of cortical network function recovery depends on localization and degree of axonal demyelination.

Cerina M, Narayanan V, Göbel K, Bittner S, Ruck T, Meuth P, Herrmann AM, Stangel M, Gudi V, Skripuletz T, Daldrup T, Wiendl H, Seidenbecher T, Ehling P, Kleinschnitz C, Pape HC, Budde T, Meuth SG.

Brain Behav Immun. 2017 Jan;59:103-117. doi: 10.1016/j.bbi.2016.08.014. Epub 2016 Aug 25.

47.

The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells.

Afzali AM, Ruck T, Herrmann AM, Iking J, Sommer C, Kleinschnitz C, Preuβe C, Stenzel W, Budde T, Wiendl H, Bittner S, Meuth SG.

Am J Physiol Cell Physiol. 2016 Oct 1;311(4):C583-C595. doi: 10.1152/ajpcell.00363.2015. Epub 2016 Aug 3.

48.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

49.

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Göbel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug TF, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schuhmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG.

Nat Commun. 2016 May 18;7:11626. doi: 10.1038/ncomms11626.

50.

Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.

Pfeuffer S, Ruck T, Kleinschnitz C, Wiendl H, Meuth SG.

Expert Rev Neurother. 2016 Jun;16(6):689-700. doi: 10.1080/14737175.2016.1176531. Epub 2016 Apr 25. Review.

PMID:
27058174

Supplemental Content

Support Center